CN100355753C - 用于制备具有治疗作用的莨菪烷衍生物的中间体 - Google Patents

用于制备具有治疗作用的莨菪烷衍生物的中间体 Download PDF

Info

Publication number
CN100355753C
CN100355753C CNB2005100068151A CN200510006815A CN100355753C CN 100355753 C CN100355753 C CN 100355753C CN B2005100068151 A CNB2005100068151 A CN B2005100068151A CN 200510006815 A CN200510006815 A CN 200510006815A CN 100355753 C CN100355753 C CN 100355753C
Authority
CN
China
Prior art keywords
formula
compound
dichloromethane
compounds
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB2005100068151A
Other languages
English (en)
Chinese (zh)
Other versions
CN1680371A (zh
Inventor
M·派洛斯
D·A·普利斯
B·L·C·司塔曼
A·伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0014046A external-priority patent/GB0014046D0/en
Priority claimed from GB0015835A external-priority patent/GB0015835D0/en
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN1680371A publication Critical patent/CN1680371A/zh
Application granted granted Critical
Publication of CN100355753C publication Critical patent/CN100355753C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
CNB2005100068151A 2000-05-26 2001-05-09 用于制备具有治疗作用的莨菪烷衍生物的中间体 Expired - Lifetime CN100355753C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0014046.7 2000-05-26
GB0014046A GB0014046D0 (en) 2000-05-26 2000-05-26 Compounds useful in therapy
GB0015835A GB0015835D0 (en) 2000-06-27 2000-06-27 Compounds useful in therapy
GB0015835.2 2000-06-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB018088287A Division CN1279040C (zh) 2000-05-26 2001-05-09 用于治疗的莨菪烷衍生物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2006100735840A Division CN1830445B (zh) 2000-05-26 2001-05-09 含有具有治疗作用的莨菪烷衍生物的组合物及其多晶型物

Publications (2)

Publication Number Publication Date
CN1680371A CN1680371A (zh) 2005-10-12
CN100355753C true CN100355753C (zh) 2007-12-19

Family

ID=26244452

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB2005100068151A Expired - Lifetime CN100355753C (zh) 2000-05-26 2001-05-09 用于制备具有治疗作用的莨菪烷衍生物的中间体
CNB018088287A Expired - Lifetime CN1279040C (zh) 2000-05-26 2001-05-09 用于治疗的莨菪烷衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB018088287A Expired - Lifetime CN1279040C (zh) 2000-05-26 2001-05-09 用于治疗的莨菪烷衍生物

Country Status (50)

Country Link
EP (3) EP1526134B1 (enExample)
JP (2) JP3693957B2 (enExample)
KR (2) KR100523501B1 (enExample)
CN (2) CN100355753C (enExample)
AP (1) AP1965A (enExample)
AR (2) AR028622A1 (enExample)
AT (2) ATE260914T1 (enExample)
AU (2) AU2001252482B2 (enExample)
BG (1) BG65966B1 (enExample)
BR (1) BRPI0110955B8 (enExample)
CA (1) CA2408909C (enExample)
CR (1) CR10145A (enExample)
CU (1) CU23288B7 (enExample)
CY (3) CY2008006I1 (enExample)
CZ (1) CZ299102B6 (enExample)
DE (3) DE60102233T2 (enExample)
DK (2) DK1284974T3 (enExample)
DZ (1) DZ3464A1 (enExample)
EA (2) EA005382B1 (enExample)
EE (1) EE05110B1 (enExample)
EG (1) EG24137A (enExample)
ES (3) ES2311126T3 (enExample)
FR (1) FR08C0007I2 (enExample)
GE (1) GEP20063799B (enExample)
HR (1) HRP20020938B1 (enExample)
HU (1) HU225810B1 (enExample)
IL (2) IL152531A0 (enExample)
IS (1) IS2511B (enExample)
LT (1) LTC1284974I2 (enExample)
LU (1) LU91417I2 (enExample)
MA (1) MA26902A1 (enExample)
ME (1) ME00555B (enExample)
MX (1) MXPA02011631A (enExample)
MY (3) MY131019A (enExample)
NL (1) NL300338I2 (enExample)
NO (3) NO327892B1 (enExample)
NZ (1) NZ521477A (enExample)
OA (1) OA12264A (enExample)
PA (1) PA8517101A1 (enExample)
PE (1) PE20011371A1 (enExample)
PL (1) PL200551B1 (enExample)
PT (2) PT1526134E (enExample)
RS (2) RS51436B (enExample)
SI (2) SI1526134T1 (enExample)
SK (1) SK286129B6 (enExample)
TN (1) TNSN01077A1 (enExample)
TR (1) TR200400541T4 (enExample)
TW (1) TWI230160B (enExample)
UY (1) UY26727A1 (enExample)
WO (1) WO2001090106A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104402883A (zh) * 2014-10-24 2015-03-11 艾琪康医药科技（上海）有限公司 4,4-二氟金刚烷甲酰胺衍生物、药物组合物及其制备方法和用途

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1526134B1 (en) * 2000-05-26 2008-09-03 Pfizer Limited Triazolyl tropane derivatives as ccr5 modulators
WO2002100848A1 (en) * 2001-06-12 2002-12-19 Sk Corporation Novel phenylalkyl diamine and amide analogs
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0200919D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
EA007590B1 (ru) * 2002-04-08 2006-12-29 Пфайзер Инк. Производные тропана в качестве модуляторов ccr5
GB0208071D0 (en) * 2002-04-08 2002-05-22 Pfizer Ltd Tropane derivatives useful in therapy
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
MXPA04011577A (es) * 2002-05-23 2005-03-07 Pfizer Metodo para la identificacion de un ligando, por el cual se mide el tiempo de residencia del receptor.
WO2004054581A2 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
DE10336274A1 (de) * 2003-08-07 2005-03-10 Honeywell Specialty Chemicals Verfahren zur Herstellung von geminalen Difluoralkanen
RU2387646C2 (ru) 2003-08-29 2010-04-27 Рэнбакси Лабораториз Лимитед Ингибиторы фосфодиэстеразы типа-iv
CA2579609A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
ES2295924T3 (es) * 2003-10-03 2008-04-16 Pfizer, Inc. Derivados de tropano imidazopirina sustituidos con actividad antagonista de los receptores ccr5 para el tratamiento de vih y de la inflamacion.
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
ATE382623T1 (de) 2004-06-09 2008-01-15 Hoffmann La Roche Octahydropyrrolo(3,4-c)pyrrolderivate und deren verwendung als antivirale mitteln
EP1814549A2 (en) * 2004-11-19 2007-08-08 Boehringer Ingelheim International GmbH Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
WO2006064340A2 (en) * 2004-12-13 2006-06-22 Pfizer Limited Process for the preparation of n-acyl beta-aminoaldehydes
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
EP1910573B1 (en) 2005-07-22 2013-09-04 CytoDyn, Inc. Methods for reducing viral load in hiv-1-infected patients
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
KR20090013827A (ko) * 2006-06-12 2009-02-05 화이자 프로덕츠 인크. Ｈｉｖ 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ｃｃｒ５ 길항제
DE602007013573D1 (de) 2006-08-16 2011-05-12 Hoffmann La Roche Nicht-nukleosidische reverse-transkriptase-hemmer
WO2008063600A2 (en) * 2006-11-17 2008-05-29 Concert Pharmaceuticals Inc. Triazolyl tropane derivatives
ES2550152T3 (es) 2006-12-13 2015-11-04 F. Hoffmann-La Roche Ag Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa
US20080146605A1 (en) * 2006-12-19 2008-06-19 Auspex Pharmaceuticals, Inc. Preparation and utility of ccr5 inhibitors
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
WO2008132128A2 (en) * 2007-04-27 2008-11-06 Solvay (Société Anonyme) Synthesis of a pharmaceutically active compound
RU2368613C1 (ru) * 2008-02-19 2009-09-27 Институт молекулярной генетики Российской Академии наук (ИМГ РАН) (Статус Государственного учреждения) Равномерно меченный тритием 4,4-дифтор-n-{(1s)-3-[3-(3-изопропил-5-метил-4н-1,2,4-триазол-4-ил)-8-азабицикло[3.2.1]окт-8-ил]-1-фенилпропил}циклогексан карбодиимид
JP2011513317A (ja) * 2008-02-29 2011-04-28 シェーリング コーポレイション Ｈｉｖ感染を防止するための予防薬としてのｃｃｒ５アンタゴニストおよびｈｉｖの伝播を抑制する方法
CN101712679B (zh) * 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途
JP5730871B2 (ja) * 2009-07-24 2015-06-10 グラクソスミスクライン エルエルシー 治療化合物
CN102140104B (zh) * 2010-02-03 2014-11-12 中国科学院上海药物研究所 1-(3-(s)-氨基丙基)-哌啶-4-氨基酰胺类化合物、其药物组合物及其制备方法和用途
MX2012011415A (es) 2010-04-02 2013-02-26 Phivco 1 Llc Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico.
CN103159754A (zh) * 2011-12-19 2013-06-19 中国科学院上海药物研究所 一种氨基丙基取代托烷胺类化合物、其药物组合物及其制备方法和用途
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CZ306455B6 (cs) 2013-04-26 2017-02-01 Zentiva, K.S. Nový způsob syntézy Maravirocu
CN103497164B (zh) * 2013-09-23 2015-12-23 西安近代化学研究所 一种蒽衍生物及其制备方法
CN104304248B (zh) * 2014-10-23 2016-08-10 西北农林科技大学 3-芳基丙酸酯类化合物作为制备杀螨药物的应用
CN104387379B (zh) * 2014-11-26 2017-01-11 扬州氟药科技有限公司 一种二氟亚甲基哌啶甲酰胺衍生物及其制备方法和用途
CN104860946A (zh) * 2015-05-14 2015-08-26 湖北生物医药产业技术研究院有限公司 Ccr5拮抗剂的制备方法
CN107879963A (zh) * 2016-09-29 2018-04-06 中国科学院上海药物研究所 新型手性配体、金属螯合物、多种非天然氨基酸、马拉维诺及其关键中间体的合成方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1999004794A1 (en) * 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
WO1999017773A1 (en) * 1997-10-07 1999-04-15 Smithkline Beecham Corporation Compounds and methods

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5648511A (en) * 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
FR2676444B1 (fr) * 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
CN1043763C (zh) * 1994-04-19 1999-06-23 纽罗研究公司 莨菪烷衍生物及其制备方法和应用
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
DE19546462A1 (de) * 1995-12-13 1997-06-19 Bayer Ag Diarylacetylenketone
WO1997024325A1 (en) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
JP2000516210A (ja) * 1996-07-12 2000-12-05 ロイコサイト，インコーポレーテッド ケモカインレセプターアンタゴニストとその使用方法
WO1998025604A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
WO1999037619A1 (en) * 1998-01-21 1999-07-29 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
EP1013276A1 (en) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
EP1526134B1 (en) * 2000-05-26 2008-09-03 Pfizer Limited Triazolyl tropane derivatives as ccr5 modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1999004794A1 (en) * 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
WO1999017773A1 (en) * 1997-10-07 1999-04-15 Smithkline Beecham Corporation Compounds and methods

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104402883A (zh) * 2014-10-24 2015-03-11 艾琪康医药科技（上海）有限公司 4,4-二氟金刚烷甲酰胺衍生物、药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
NO2020019I1 (no) 2020-06-30
EP1990341B1 (en) 2013-01-23
ES2311126T3 (es) 2009-02-01
IL152531A0 (en) 2003-05-29
ME00555A (en) 2011-12-20
TNSN01077A1 (fr) 2005-11-10
CY2008006I2 (el) 2009-11-04
WO2001090106A2 (en) 2001-11-29
EP1526134A2 (en) 2005-04-27
CN1680371A (zh) 2005-10-12
CN1279040C (zh) 2006-10-11
ES2215129T3 (es) 2004-10-01
DE122008000011I1 (de) 2008-06-05
ME00555B (me) 2011-12-20
PE20011371A1 (es) 2002-01-18
PL359267A1 (en) 2004-08-23
CY2022009I2 (el) 2022-05-27
HK1078573A1 (en) 2006-03-17
HK1090836A1 (en) 2007-01-05
BR0110955A (pt) 2003-06-03
NO327892B1 (no) 2009-10-12
IL152531A (en) 2010-05-17
BG107140A (bg) 2003-05-30
ATE260914T1 (de) 2004-03-15
MY131019A (en) 2007-07-31
ATE407134T1 (de) 2008-09-15
AU2001252482C1 (en) 2001-12-03
DK1526134T3 (da) 2008-11-17
IS2511B (is) 2009-05-15
AP2002002663A0 (en) 2002-12-31
AR028622A1 (es) 2003-05-14
KR100523501B1 (ko) 2005-10-25
EP1284974A2 (en) 2003-02-26
AU5248201A (en) 2001-12-03
DE60102233D1 (de) 2004-04-08
NO2010007I2 (no) 2013-09-09
EE200200656A (et) 2004-06-15
NZ521477A (en) 2004-07-30
PT1526134E (pt) 2008-10-28
CY1108451T1 (el) 2014-04-09
ES2401812T3 (es) 2013-04-24
MY153023A (en) 2014-12-31
LTPA2008004I1 (lt) 2020-07-27
BG65966B1 (bg) 2010-07-30
KR20050046743A (ko) 2005-05-18
HK1054927A1 (en) 2003-12-19
DE60135685D1 (de) 2008-10-16
SK16432002A3 (sk) 2004-01-08
CY2008006I1 (el) 2009-11-04
HUP0302474A2 (hu) 2003-11-28
MY156920A (en) 2016-04-15
EA200401056A1 (ru) 2005-04-28
LU91417I2 (fr) 2008-04-22
OA12264A (en) 2003-11-10
NO20025227D0 (no) 2002-10-31
SI1526134T1 (sl) 2008-12-31
CY2022009I1 (el) 2022-05-27
NL300338I1 (nl) 2008-05-01
SK286129B6 (sk) 2008-04-07
EP1284974B1 (en) 2004-03-03
AR060159A2 (es) 2008-05-28
TR200400541T4 (tr) 2004-04-21
CR10145A (es) 2008-08-19
PT1284974E (pt) 2004-06-30
IS6565A (is) 2002-09-24
FR08C0007I2 (fr) 2009-01-15
WO2001090106A3 (en) 2002-03-28
EP1990341A1 (en) 2008-11-12
CN1437599A (zh) 2003-08-20
MA26902A1 (fr) 2004-12-20
CA2408909A1 (en) 2001-11-29
HU225810B1 (en) 2007-10-29
EA200201141A1 (ru) 2003-04-24
LU91417I9 (enExample) 2019-01-02
EA005382B1 (ru) 2005-02-24
RS51436B (sr) 2011-04-30
EE05110B1 (et) 2008-12-15
NL300338I2 (nl) 2008-06-02
JP2003534343A (ja) 2003-11-18
NO20025227L (no) 2002-10-31
KR100548854B1 (ko) 2006-02-02
PA8517101A1 (es) 2002-10-24
GEP20063799B (en) 2006-04-25
EP1526134B1 (en) 2008-09-03
NO2010007I1 (no) 2010-04-08
DE60102233T2 (de) 2005-01-27
RS50904B (sr) 2010-08-31
EA007580B1 (ru) 2006-12-29
TWI230160B (en) 2005-04-01
PL200551B1 (pl) 2009-01-30
JP3693957B2 (ja) 2005-09-14
KR20030004417A (ko) 2003-01-14
JP2005194283A (ja) 2005-07-21
CZ20023806A3 (cs) 2004-01-14
HRP20020938B1 (en) 2011-05-31
CU23288B7 (es) 2008-06-30
RS20090438A (sr) 2010-05-07
EP1526134A3 (en) 2006-11-29
DZ3464A1 (enExample) 2001-11-29
BRPI0110955B1 (pt) 2016-06-28
MXPA02011631A (es) 2003-03-27
DK1284974T3 (da) 2004-06-07
AP1965A (en) 2009-03-04
FR08C0007I1 (enExample) 2008-04-25
SI1284974T1 (en) 2004-08-31
CA2408909C (en) 2006-06-27
CZ299102B6 (cs) 2008-04-23
UY26727A1 (es) 2001-12-28
YU82202A (sh) 2005-11-28
HRP20020938A2 (en) 2005-02-28
BRPI0110955B8 (pt) 2021-05-25
HUP0302474A3 (en) 2007-05-29
LTC1284974I2 (lt) 2020-11-10
EG24137A (en) 2008-08-06
AU2001252482B2 (en) 2006-01-19
JP4854970B2 (ja) 2012-01-18

Similar Documents

Publication Publication Date Title
EP1526134B1 (en) Triazolyl tropane derivatives as ccr5 modulators
US7576097B2 (en) Tropane derivatives useful in therapy
AU2001252482A1 (en) Triazolyl Tropane Derivatives as CCR5 Modulators
CN1830445B (zh) 含有具有治疗作用的莨菪烷衍生物的组合物及其多晶型物
HK1078573B (en) Tropane derivatives useful in therapy
HK1090836B (en) Intermediates for the preparation of tropane derivatives useful in therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1078573

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1078573

Country of ref document: HK

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20071219